SEC Company Response from ORAMED PHARMACEUTICALS INC. (ORMP) (CIK 0001176309) (ORMP) — Jul 22, 2021
ORAMED PHARMACEUTICALS INC. (ORMP) (CIK 0001176309)
Date: July 22, 2021 · CIK: 0001176309 · Accession: 0001213900-21-038057
AI Filing Summary & Sentiment
File numbers found in text: 333-257926
Letter
VIA EDGAR Division of Corporation Finance United States Securities and Exchange Commission Washington, D.C. 20549 Registration Statement on Form S-3 File No. 333-257926
Re: Oramed Pharmaceuticals Inc.
Dear Sir or Madam:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Oramed Pharmaceuticals Inc. (the “Registrant”) hereby requests that the effective date of the above-referenced registration statement be accelerated so that it will be declared effective at 4:30 p.m., Eastern Time, on July 26, 2021, or as soon as practicable thereafter.
The Registrant respectfully requests that it be notified of such effectiveness by a telephone call to Howard E. Berkenblit of Sullivan & Worcester LLP at (617) 338-2979 and that such effectiveness also be confirmed in writing.
Very truly yours,
Oramed Pharmaceuticals Inc.
Show Raw Text
CORRESP
1
filename1.htm
July
22, 2021
VIA
EDGAR
Christine
Westbrook
Division
of Corporation Finance
United
States Securities and Exchange Commission
100
F Street, NE
Washington,
D.C. 20549
Re: Oramed
Pharmaceuticals Inc.
Registration
Statement on Form S-3
File
No. 333-257926
Dear
Sir or Madam:
Pursuant
to Rule 461 under the Securities Act of 1933, as amended, Oramed Pharmaceuticals Inc. (the “Registrant”) hereby requests
that the effective date of the above-referenced registration statement be accelerated so that it will be declared effective at 4:30 p.m.,
Eastern Time, on July 26, 2021, or as soon as practicable thereafter.
The
Registrant respectfully requests that it be notified of such effectiveness by a telephone call to Howard E. Berkenblit of Sullivan &
Worcester LLP at (617) 338-2979 and that such effectiveness also be confirmed in writing.
Very truly yours,
Oramed Pharmaceuticals Inc.
By:
/s/
David Silberman
Name:
David Silberman
Title:
Chief Financial Officer
Oramed Ltd. | 1185 Avenue
of the Americas, New York, NY 10036 | www.oramed.com
Phone: + 1-844-967-2633|
Fax: +972-2-566 0004 | Email: info@oramed.com